Global Biologics and Biosimilars Market Research Report, Competitive, Technology and Forecast Analysis 2025-2032

Market Overview

According to DIResearch＇s in-depth investigation and research, the global Biologics and Biosimilars market size will reach 32,339 Million USD in 2025 and is projected to reach 46,176 Million USD by 2032, with a CAGR of 5.22% (2025-2032). Notably, the China Biologics and Biosimilars market has changed rapidly in the past few years. By 2025, China＇s market size is expected to be  Million USD, representing approximately  % of the global market share.

Research Summary

Biologics are pharmaceutical drugs derived from living organisms, such as proteins, antibodies, or nucleic acids. They are produced using biotechnology processes and are used for the treatment of various diseases, including cancer, autoimmune disorders, and genetic diseases. Biologics are often highly complex and require specialized manufacturing techniques to ensure their safety, efficacy, and consistency. Biosimilars, on the other hand, are biological products that are highly similar to an already approved reference biologic. They are developed to have comparable efficacy, safety, and quality to the reference product and undergo rigorous testing to demonstrate similarity. Biosimilars offer a more affordable alternative to the original biologic, providing increased access to life-saving therapies. They are regulated by health authorities to ensure their quality, efficacy, and safety. Biologics and biosimilars have revolutionized the field of medicine, offering innovative and effective treatment options for patients with various medical conditions.

The major global suppliers of Biologics and Biosimilars include Roche, Amgen, AbbVie, Sanofi, Johnson & Johnson, Pfizer, Novo Nordisk, Eli Lilly, Novartis, Merck, Biogen, Celltrion, Sobi, 3SBIO, Changchun High Tech, Kanghong Pharma, Innovent Biologics, Gan&Lee, Tonghua Dongbao, United Laboratory, etc. The global players competition landscape in this report is divided into three tiers. The first tier comprises global leading enterprises that command a substantial market share, hold a dominant industry position, possess strong competitiveness and influence, and generate significant revenue. The second tier includes companies with a notable market presence and reputation; these firms actively follow industry leaders in product, service, or technological innovation and maintain a moderate revenue scale. The third tier consists of smaller companies with limited market share and lower brand recognition, primarily focused on local markets and generating comparatively lower revenue.

This report studies the market size, price trends and future development prospects of Biologics and Biosimilars. Focus on analysing the market share, product portfolio, prices, sales, revenue and gross profit margin of global major suppliers, as well as the market status and trends of different product types and applications in the global Biologics and Biosimilars market. The report data covers historical data from 2020 to 2024, based year in 2025 and forecast data from 2026 to 2032.

The regions and countries in the report include US, Germany, Japan, China, France, UK, South Korea, Canada, Italy, Russia, Mexico, Brazil, India, Vietnam, Thailand, South Africa and other regions, covering the Biologics and Biosimilars market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Biologics and Biosimilars industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.

The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.

Global Key Suppliers of Biologics and Biosimilars Include:

Roche

Amgen

AbbVie

Sanofi

Johnson & Johnson

Pfizer

Novo Nordisk

Eli Lilly

Novartis

Merck

Biogen

Celltrion

Sobi

3SBIO

Changchun High Tech

Kanghong Pharma

Innovent Biologics

Gan&Lee

Tonghua Dongbao

United Laboratory

Biologics and Biosimilars Product Segment Include:

Monoclonal Antibodies

Interferon

Insulin

Vaccines

Others

Biologics and Biosimilars Product Application Include:

Hospital

Retail Pharmacy

Other

Chapter Scope

Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trend

Chapter 2: Global Biologics and Biosimilars Industry PESTEL Analysis

Chapter 3: Global Biologics and Biosimilars Industry Porter's Five Forces Analysis

Chapter 4: Global Biologics and Biosimilars Major Regional Market Size (Revenue) and Forecast Analysis

Chapter 5: Global Biologics and Biosimilars Competitive Analysis of Key Suppliers (Revenue, Market Share, Regional Distribution and Industry Concentration)

Chapter 6: Global Biologics and Biosimilars Revenue and Forecast Analysis by Product Type

Chapter 7: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)

Chapter 8: Industrial Chain Analysis, Biologics and Biosimilars Different Application Market Analysis (Revenue and Forecast) and Sales Channel Analysis

Chapter 9: Research Findings and Conclusion

Chapter 10: Methodology and Data Sources